BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing regimen. Extra contributors are going to be enrolled for the identified monotherapy dosign program. In Section B, participants will obtain oral ruxolitinib and ABBV-744 will probably be given as "add-on" therapy. In Section C, participant